Downward move for $NVAX by 34% continued today, with top reasons including concerns around COVID vaccine profitability due to company's offer of $125m shares and failing to receive support/endorsement from U.K. vaccine authorities which halved the deal to supply vaccines to this country. 

To keep investor confidence, Novavax reiterated its full-year forecast for revenue of $2 billion but confidence in future promise of returns is far too shaken. Do you think we can trust the management or is it all B.S?

Powered by Froala Editor